MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patien ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other jurisdiction o ...

Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Warrior Met Coal, Inc. (HCC) : This metallurgical coal mining company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.9% over the last 60 days.Eldorado Gold Corporation (EGO) : This mining and exploration company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.5% over the last 60 days.World Acceptance Corporation (WRLD) : This consumer finance company has seen the Zacks ...

CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Conference Call January 25, 2024 4:30 PM ET Company Participants Mike Vallie - IR Nadim Yared - President and CEO Jared Oasheim - CFO Conference Call Participants Margaret Andrew - William Blair Matthew O'Brien - Piper Sandler Robbie Marcus - JPMorgan Bill Plovanic - Canaccord Alex Nowak - Craig-Hallum Frank Takkinen - Lake Street Operator Greetings, and welcome to the CVRx Fourth Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is ...

CVRx (CVRX) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this medical device company would post a loss of $0.57 per share when it actually produced a loss of $0.43, delivering a surprise of 24.56%.Over the last four quarters, the company has surpass ...

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events ...

CVRx, Inc. (NASDAQ:CVRX) Q3 2023 Earnings Conference Call October 26, 2023 5:30 PM ET Company Participants Mike Vallie - SVP-ICR Westwicke Nadim Yared - President and CEO Jared Oasheim - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Margaret Kaczor - William Blair Alex Nowak - Craig-Hallum Frank Takkinen - Lake Street Capital Markets Operator Greetings and welcome to the CVRx Third Quarter 2023 Earnings Call. At this time all participants are in listen-only mode. A question-and-answer ses ...